The US has always had a turbulent relationship with cannabis. The substance has often been portrayed as a villainous, addictive, mind-altering drug, with harrowing consequences if used even once,
Health Minister Andrew Green confirmed last year that following advice from the Jersey Misuse of Drugs Advisory Council he was looking into legalising certain medicinal cannabis products and added that he could lodge proposals to legalise certain medicines before the end of 2017.
even though dope consumption is now legal in the state, non-citizens could still land themselves in hot water for indulging. It could have serious consequences should you ever wish to live there full-time.
Visitors will eventually tour the facilities where small farmers test, dry, cure, trim, process, and package marijuana for distribution
Second-Hand Exposure of Staff Administering Vaporised Cannabinoid Products to Patients in a Hospital Setting
In many health settings, administration of medicinal cannabis poses significant implementation barriers including drug storage and safety for administering staff and surrounding patients. Different modes of administration also provide different yet potentially significant issues. One route that has become of clinical interest owing to the rapid onset of action and patient control of the inhaled amount (via breath timing and depth) is that of vaporisation of cannabinoid products. Although requiring a registered therapeutic device for administration, this is a relatively safe method of intrapulmonary administration that may be particularly useful for patients with difficulty swallowing, and for those in whom higher concentrations of cannabinoids are needed quickly. Research results are reassuring for hospital and clinical trial practices with staff administering vaporised cannabinoid products, and helpful to ethics committees wishing to quantify risk.
Cannabinoids appear to possess many potential medical uses, which may extend to pain control. A narrative review of the literature has found a variety of studies testing botanical and synthetic cannabinoids in different pain syndromes (acute pain, cancer pain, chronic noncancer pain, fibromyalgia pain, migraine, neuropathic pain, visceral pain, and others). Results from these studies are mixed; cannabinoids appear to be most effective in controlling neuropathic pain, allodynia, medication-rebound headache, and chronic noncancer pain. A great deal more remains to be elucidated about cannabinoids which may emerge to play an important role in the treatment of neuropathic and possibly other painful conditions. There remains a great deal more to learn about the role of cannabinoids in pain management.
Germany’s medical marijuana users are people tired of popping powerful pills to ease pain. Facing a cannabis import crisis, the country is now starting to grow its own.
For the thousands of Vermonters who choose to use recreationally, what will the equivalent of a “drink responsibly” campaign for cannabis look like? “Toke thoughtfully”? “Warning: Objects may appear more edible than they are”?
So how do you know exactly which herb will be the most beneficial for your ailment? How can Florida’s doctors, many of whom have never prescribed medical marijuana, know which strain, concentration, and dosage is right for their patients?
While the Italian Ministry of Defence currently produces medical cannabis for the domestic market, certain wholesalers are permitted to purchase directly from the Dutch Office of Medical Cannabis, a sharp rise in demand has led to the government seeking external parties to provide additional supply.